Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H
Department of Internal Medicine, Hyogo Prefectural Awaji Hospital, Japan.
Haemostasis. 1992;22(4):179-86. doi: 10.1159/000216317.
We investigated the imbalance between thrombin and plasmin activity in vivo with various grades of severity of disseminated intravascular coagulation (DIC) in relation to the underlying diseases. Plasma thrombin-antithrombin-III complex (TAT) and plasmin-alpha 2-antiplasmin complex (PAP) levels were measured in 133 blood samples obtained from patients with DIC. The TAT/PAP ratio was higher in patients with sepsis or solid cancer than in those with hematologic malignancies. In acute promyelocytic leukemia (APL), the TAT levels were the highest, but the PAP levels were even higher and the TAT/PAP ratio was the lowest. As for the severity of DIC, in mild DIC, both thrombin and plasmin activities were increased. In moderate DIC, the TAT/PAP ratio increased, and thrombin activity was much more predominant. However, in severe DIC, the ratio decreased, and plasmin activity became excessive. In 3 patients with acute myeloblastic leukemia, APL and pancreatic cancer, respectively, the PAP level remained high during heparin therapy although the TAT level was decreased. When tranexamic acid was given, the PAP level was selectively reduced, and the TAT/PAP ratio was markedly decreased along with clinical improvement. These results indicate that monitoring of the TAT/PAP ratio may contribute to decisions regarding the institution and performance of combination therapy for DIC using anticoagulants and antifibrinolytic agents.
我们研究了体内凝血酶和纤溶酶活性失衡与各种严重程度的弥散性血管内凝血(DIC)及相关基础疾病之间的关系。检测了133例DIC患者血样中的血浆凝血酶 - 抗凝血酶 - III复合物(TAT)和纤溶酶 - α2 - 抗纤溶酶复合物(PAP)水平。脓毒症或实体癌患者的TAT/PAP比值高于血液系统恶性肿瘤患者。在急性早幼粒细胞白血病(APL)中,TAT水平最高,但PAP水平更高,TAT/PAP比值最低。至于DIC的严重程度,轻度DIC时,凝血酶和纤溶酶活性均升高。中度DIC时,TAT/PAP比值升高,凝血酶活性更为突出。然而,在重度DIC时,该比值降低,纤溶酶活性变得过高。分别有3例急性髓细胞白血病、APL和胰腺癌患者,在肝素治疗期间PAP水平持续升高,而TAT水平降低。给予氨甲环酸后,PAP水平选择性降低,TAT/PAP比值随临床改善而显著降低。这些结果表明,监测TAT/PAP比值可能有助于决定使用抗凝剂和抗纤溶药物联合治疗DIC的时机和实施情况。